ArticleFrontiers in oncology2025
Mixed adenoneuroendocrine carcinoma of the gallbladder: a case report and review of the literature.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinoma (NEC) is a rare malignant tumor of the gallbladder (GB) and is extremely rare in medical practice. Related case reports and in-depth studies are extremely limited, resulting in an insufficient understanding of the disease. This article reports a case of a 60-year-old female patient who complained of right upper abdominal pain for 20 days. Subsequent examinations confirmed that it was mixed adenoneuroendocrine carcinoma of the gallbladder (GB-MANEC), of which the neuroendocrine part accounted for approximately 70%, and was defined as a poorly differentiated NEC. The Ki-67 index reached 80%, indicating highly aggressive behavior. Postoperative adjuvant chemotherapy was administered (six cycles of etoposide combined with cisplatin). Follow-up through December 2024 showed no signs of tumor recurrence, with a disease-free survival period of 12 months. Currently, the preferred treatment strategy for GB-NEC is radical surgery. Therefore, in this case, radical resection combined with chemotherapy became an effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.